Rapid Heart Rates Grow Faster as Drug Treatments Threaten Lives, Claims GlobalData

13 Sep 2012 • by Natalie Aster

Major safety fears over supraventricular tachycardia (SVT) medications are threatening many elderly patients, and even encouraging some to opt for surgery, claims a new report by healthcare experts GlobalData.

The new report, "Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019" shows that the prognosis for SVT is good if there are no associated co-morbidities, but with time, more frequent and long-lasting episodes are seen in almost all patients, who are forced to adhere to treatments potentially even more dangerous to their health than the condition itself.

However, some set-backs in the SVT therapeutics market may have a negative impact on patient wellbeing. Negative opinions of antiarrhythmic Multaq have emerged among physicians following the black box warning given by the US FDA on December 19, 2011, noting that the drug must be not prescribed for people with a history of heart failure.

Patients can be given adenosine (Adenocard), which is a fast-acting intravenous (IV) antiarrhythmic agent that can offer faster activation if given by IV. Adenosine treatment is highly efficacious, yet it still has uncomfortable temporary side effects, including chest pain, flushing, nausea, breathlessness, and dizziness.

SVT patients also suffer a high risk of strokes due to embolism, which can be prevented by anticoagulants such as warfarin, and the recently approved Xarelto and Pradaxa. However, the low safety profiles of such drugs due to bleeding complications mean that the prescription rate of these drugs is low.

As a result, ablation is the treatment of choice for many cardiologists. Procedures such as radiofrequency ablation have increased preference in recent years for the treatment of SVT, and boast more than 85% success rate with few complications. Due to the various risks of drug treatments, more and more cardiologists prefer procedures over medication. Other treatments can also include pacemakers, or cardioversion (an electric shock) to restore the heart’s normal rhythm.

Report Details:

Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Published: August, 2012
Pages: 88
Price: US$ 3.995,00

More information can be found in the report “Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019” by GlobalData.

To order the report or ask for sample pages contact ps@marketpublishers.com


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970